The Bio Report

→ WHAT IT COVERS Immuneering CEO Ben Zeskind explains how the company's informatics-driven "deep cyclic inhibition" approach to MEK inhibition delivers intense daily pulses rather than continuous suppression, producing 64% twelve-month overall survival in first-line pancreatic cancer patients versus 35% on standard-of-care gemcitabine/nab-paclitaxel chemotherapy.

→ WHAT IT COVERS Rheumagen CEO Richard Fried explains how the company's HLA gene editing platform targets the genetic root of autoimmune diseases. Rather than suppressing the immune system broadly, Rheumagen edits a single amino acid position in hematopoietic stem cells to permanently silence disease-triggering antigen presentation, beginning with rheumatoid arthritis.

→ WHAT IT COVERS McKinsey partner Fengning Zhang analyzes how Asia's share of the global innovative drug pipeline grew from 28% to 43% in five years, with the region contributing 85% of global pipeline growth in 2024. Zhang outlines distinct capabilities across China, Japan, India, South Korea, and Singapore and how global biopharma should respond. → KEY INSIGHTS - **Asia pipeline scale:** Asia now generates two-thirds of global patents and contributed 85% of global innovative drug pipeline...

→ WHAT IT COVERS Columbia University hematologist-oncologist Aaron Vinny, an acute lymphoblastic leukemia survivor who underwent chemotherapy, CNS relapse treatment, and allogeneic stem cell transplant at age 20, makes the case for shifting blood cancer treatment from cell-killing chemotherapy toward epigenetic reprogramming and precision cell-surface proteomics strategies.

→ WHAT IT COVERS Terns Pharmaceuticals CEO Annie Burrows explains how the company pivoted from metabolic disease to chronic myeloid leukemia after its allosteric BCR-ABL inhibitor TURN-701 achieved a 75% major molecular response rate in third-line-plus patients, compared to 25% for the current best-in-class therapy, prompting a $748M capital raise. → KEY INSIGHTS - **Allosteric vs.

→ WHAT IT COVERS Engene CEO Ron Cooper explains how Detalimigene, a nonviral gene therapy using a proprietary synthetic sugar-based polymer, delivers a dual-payload immune response directly into the bladder to treat BCG-unresponsive non-muscle invasive bladder cancer, with a pivotal 125-patient trial targeting a 2026 BLA filing and potential 2027 FDA approval. → KEY INSIGHTS - **BCG Treatment Gap:** Standard BCG immunotherapy fails roughly 30–40% of NMIBC patients, and has faced U.S.

→ WHAT IT COVERS Adaptin Bio CEO Michael Roberts explains how the company's BRITE platform uses patient-derived T cells as delivery vehicles to transport bispecific therapeutic payloads across the blood-brain barrier, with lead program APTN-101 targeting glioblastoma and a Phase 1 trial planned for early 2026. → KEY INSIGHTS - **Blood-Brain Barrier Delivery Gap:** Current BBB-crossing strategies — including focused ultrasound with microbubbles, receptor-mediated transcytosis, and...

→ WHAT IT COVERS Marc Tessier-Lavigne, co-founder and CEO of Xara, explains how the company deploys over $1 billion in funding to apply end-to-end AI across three drug development bottlenecks: target identification, molecular design, and patient stratification, with an initial focus on historically undruggable biological targets. → KEY INSIGHTS - **Causal vs.

→ WHAT IT COVERS Faraz Chowdhury, cofounder and CEO of Immunoscientific, explains how the company's AI-enabled structural surfaceomics platform identifies disease-specific protein conformations to create cancer therapies with selectivity ratios exceeding 1,000-to-1, targeting AML as its lead program with an IND planned for 2027. → KEY INSIGHTS - **Toxicity as root cause:** Approximately one-third of all clinical drug failures stem from toxicity and safety issues, a rate that worsens in oncology...

→ WHAT IT COVERS Nanology Managing Director Mark Iacobucci explains how the company's Large Surface Area Microparticle (LSAM) platform engineers existing oncology drugs into microparticles for direct intratumoral injection, achieving sustained high-concentration local drug release across six solid tumor types while eliminating systemic chemotherapy toxicity in 140 patients across seven trials.

→ WHAT IT COVERS Valerie Daggett, founder and CEO of AltPep, explains how her company targets alpha sheet toxic oligomers — structural precursors to Alzheimer's plaques detectable up to 16 years before symptoms — using synthetic peptides designed to both diagnose and neutralize these early-stage disease triggers. → KEY INSIGHTS - **Early detection window:** Alpha sheet toxic oligomers form 10–30 years before Alzheimer's symptoms appear, making them detectable far earlier than amyloid plaques...